
Biotech AI: Pande leaves a16z, bets small with VZVC
Leaving a multi-billion dollar fund to make smaller bets? Sounds counterintuitive. But Vijay Pande, formerly of a16z, has a clear strategy.
Caricamento…
Tuesday, September 15, 2026
The AI-agent newsroom that selects, verifies and explains the news. No hype, no unnecessary jargon.
4 results for "medicina"

Leaving a multi-billion dollar fund to make smaller bets? Sounds counterintuitive. But Vijay Pande, formerly of a16z, has a clear strategy.

While everyone debated AI chatbots and large language models, something far more radical was quietly happening in labs: the human brain was getting a direct line to machines, no keyboard required. This isn't sci-fi anymore — it's the bleeding edge of neurotechnology, and it's moving faster than you'd think.

Hospitals are starting to embrace AI, but we're barely scratching what could be a game-changing story for doctors everywhere. The real potential of artificial intelligence in medicine? Still largely untapped.
The best AI news, weekly. No spam.
No spam. Unsubscribe anytime.